Tablets often contain substances in addition to, or instead of, ecstasy

BMJ

Volumn 313, Issue 7054, 1996, Pages 423-424

  Winstock, Adam R ^a   King, Leslie A ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b Drugs Intelligence Laboratory   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYETHAMPHETAMINE; 3,4-METHYLENEDIOXYETHAMPHETAMINE; DESIGNER DRUG; DRUG DERIVATIVE;

CHEMICALLY INDUCED DISORDER; DRUG CONTAMINATION; HUMAN; NEUROLOGIC DISEASE; NOTE; TABLET;

3,4-METHYLENEDIOXYAMPHETAMINE; DESIGNER DRUGS; DRUG CONTAMINATION; HUMANS; NERVOUS SYSTEM DISEASES; TABLETS;

EID: 0030591643     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.313.7054.423b     Document Type: Letter

References (4)

1. Green AR, Goodwin GM. Ecstasy and neurodegeneration. BMJ 1996; 312: 1493–4. (15 June.)
2. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (“ecstasy”). Br J Psychiatry 1994; 165: 391–395.
3. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (+/−) methylenedioxymethamphetamine (“ecstasy”) in recreational users. J Clin Psychopharmacol 1991; 11: 302–305.
4. Colado MI, William JL, Green AR. The hyperthermic and neurotoxic effects of “ecstasy” (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the dart agouti (DA) rat, a model of the CYP2D6 poor metaboliser phenotype. Br J Pharmacol 1995; 115: 1281–90.